Abstract: A magnetic peg-board activity planning/scheduling system for arrangement in a horizontal or vertical display orientation, comprising: a metallic-based pegboard panel assembly including a magnetic-steel sheet, and a peg apertured panel made of thin material through which a plurality of peg apertures are formed in a uniform manner, and being mounted and held together within a framework, wherein a plurality of peg apertures are formed in a uniform manner through the peg apertured panel; and a set of magnetic peg-based indicating tiles, each having a peg structure that is adapted for physically coupling to the peg apertures in the metallic-based pegboard panel and magnetically coupling to the magnetic-steel sheet in a releasable manner to selective changing the placement of the magnetic peg-based indicating tile on the surface of the metallic-based pegboard panel; wherein each magnetic peg-based indicating tile component includes an indicating graphic representative of an activity and/or indicating text represent

Abstract: While eliminating a protein of interest in a eukaryotic organism is relatively straightforward, non-GMO methods based on nucleotide substitutions for modulating the translational efficiency and levels of a protein towards a pre-determined aim have proven difficult. This is due to the complexity of the protein expression machinery which makes it difficult to predict and elucidate the effects of a substitution in a nucleotide sequence on the modulation of an endogenous protein expression. The present invention relates to a method for modulating levels of a protein of interest in a eukaryotic organism of a species of interest, leading to increasing the probability of either higher or lower levels of the protein of interest. Further, the present invention relates to an eukaryotic organism comprising one or more mutation(s) associated with this modulation.

Abstract: Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.

Abstract: This application relates to new C-type natriuretic peptide (CNP) compounds, pharmaceutical compositions comprising these compounds, and these compounds for use as medicaments.

Abstract: This application relates to new C-type natriuretic peptide (CNP) compounds, pharmaceutical compositions comprising these compounds, and these compounds for use as medicaments.

Abstract: A gaming headset system for use in a game event. A headset (HS) has a mouth microphone (MM), and a headphone with over-the-car car-cups (EC) each having inside a loudspeaker transducer (LT) and a feed-back microphone (FB). A feed-forward microphone (FF) is placed on an exterior part of the car-cups (EC). An ambient noise and speech suppression system (ANSS) serves to attenuate ambient noise and suppress intelligibility of ambient speech sound reaching the gamer (GM) in response to input signals indicative of sound captured by one or more of: 1) the mouth microphone (MM). 2) the feed-forward microphones (FF), 3) the feed-back microphones (FB), and 4) one or more sources (GSP_I. AUDM) located external to the car-cups (EC).

Abstract: An insulated container can include a body having a length, width and height. The body can include an interior volume, an internal rim and an internal slot extending into the interior volume. The insulated container can further include a lid. The lid can have an open position and a closed position. The insulated container can have a cutting board. The cutting board can be complementary in shape to the internal rim and seat on the internal rim. The cutting board also can seat in the internal slot.

Abstract: Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.

Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogs and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogs and derivatives thereof as medicaments.

Abstract: A microphone assembly comprising: a microphone for converting an acoustic signal to an electrical microphone signal; a tube enclosing at least a part of a first conductor for conducting the microphone signal, the tube comprising a rigid first tube part and a rigid second tube part. The first tube part has a first primary tube end and a first secondary tube end, wherein the microphone is attached at the first primary tube end. The second tube part has a second primary tube end and a second secondary tube end. A first rotating connector between the first tube part and the second tube part allows rotating the first tube part in relation to the second tube part about a first rotation axis.

Abstract: A microphone system includes a microphone with a microphone output for converting a first acoustic audio signal to a microphone signal, the system including: a head part including a loudspeaker with a loudspeaker input for converting a loudspeaker signal to a second acoustic audio signal; a first connector for connecting the system to an auxiliary device and including a housing and a first terminal; a unit for preprocessing the microphone signal having at least a first input connected to the microphone output, a first output connected to the loudspeaker input, and a second output connected to the first terminal. The unit is configured to: receive the microphone signal on the first input to form a input signal; and process the input signal to form first and second output signals on the first and second outputs, respectively, the first output signal and the second output signal based on the input signal.

Abstract: A microphone system including: an ear hook including a body member, a hook part and an output member; a microphone boom; a microphone connected to a first conductor and mounted on the microphone boom; a loudspeaker connected to a second conductor, wherein the microphone system is configured to feed an acoustic audio signal from the first loudspeaker via the output member; and an electrical connector for connecting the microphone system to an auxiliary device.

Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogues and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogues and derivatives thereof as medicaments.

Abstract: A microphone assembly is disclosed, the microphone assembly comprising: a microphone for converting an acoustic signal to an electrical microphone signal; and a rigid tube with a first tube end and a second tube end. The microphone is attached at the first tube end. The rigid tube encloses at least a part of a first conductor for conducting the microphone signal. The rigid tube has a first tube part extending along a first axis, and the rigid tube has a first bend between the first tube end and the first tube part. A clamp member is mounted on the rigid tube, wherein the clamp member is configured for clamping the microphone assembly to a piece of clothing placed between a clamping section of the rigid tube and a clamping section of the clamp member.

Abstract: A microphone assembly comprising: a microphone for converting an acoustic signal to an electrical microphone signal; a tube enclosing at least a part of a first conductor for conducting the microphone signal, the tube comprising a rigid first tube part and a rigid second tube part. The first tube part has a first primary tube end and a first secondary tube end, wherein the microphone is attached at the first primary tube end. The second tube part has a second primary tube end and a second secondary tube end. A first rotating connector between the first tube part and the second tube part allows rotating the first tube part in relation to the second tube part about a first rotation axis.

Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogues and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogues and derivatives thereof as medicaments.

Abstract: A microphone assembly is disclosed, the microphone assembly comprising: a microphone for converting an acoustic signal to an electrical microphone signal; and a rigid tube with a first tube end and a second tube end. The microphone is attached at the first tube end. The rigid tube encloses at least a part of a first conductor for conducting the microphone signal. The rigid tube has a first tube part extending along a first axis, and the rigid tube has a first bend between the first tube end and the first tube part. A clamp member is mounted on the rigid tube, wherein the clamp member is configured for clamping the microphone assembly to a piece of clothing placed between a clamping section of the rigid tube and a clamping section of the clamp member.

Abstract: The invention concerns a soluble pharmaceutical formulation comprising an insulin derivative wherein the formulation further comprises more than 4 zinc atoms per 6 molecules of the insulin derivative, and a citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers. The invention further comprises a process for preparing the soluble pharmaceutical formulation.

Abstract: Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.